Laboratorios Farmaceuticos RoviLABFF 93 Equity-to-Asset is 0.73 as of Mar. 2026, which is 12% above its 10-year median of 0.65. GuruFocus rates LABFF with a GF Score™ of 93/100 and a GF Value™ of $82.42. The stock has 1 warning sign investors should review. Among 1,007 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks better than 69.51% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Laboratorios Farmaceuticos Rovi Equity-to-Asset Related Terms
Laboratorios Farmaceuticos Rovi Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LABFF vs ZTS, UTHR, VTRS: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi (LABFF) has a Equity-to-Asset of 0.73 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is 12% above median its historical median of 0.65. Over the past decade, Laboratorios Farmaceuticos Rovi's Equity-to-Asset has ranged from 0.50 to 0.73. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #307 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 30.5%.
Is Laboratorios Farmaceuticos Rovi's Equity-to-Asset too high?
Laboratorios Farmaceuticos Rovi's current Equity-to-Asset of 0.73 is 12% above median its 10-year median of 0.65. Over the past 10 years, this metric has ranged from a low of 0.50 to a high of 0.73. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Laboratorios Farmaceuticos Rovi's value of 0.73 is 19.7% above this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #307 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #307 out of 1007 companies for Equity-to-Asset. This puts Laboratorios Farmaceuticos Rovi in the upper half of its industry. The industry median Equity-to-Asset is 0.61. Laboratorios Farmaceuticos Rovi's value of 0.73 is 19.7% above this benchmark. Historically, Laboratorios Farmaceuticos Rovi's own Equity-to-Asset has ranged from 0.50 to 0.73 over the past decade. While the company's 10-year median is 0.65 vs. the industry median of 0.61, Laboratorios Farmaceuticos Rovi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current Equity-to-Asset of 0.73 is 19.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current Equity-to-Asset is 0.73, which is 12% above median its own 10-year median of 0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (LABFF) has a current Equity-to-Asset of 0.73. The stock's GF Value™ is $82.42, compared to a current price of $90.61 — trading 9.9% above its estimated fair value. The current Equity-to-Asset is 0.73, which is 12% above median its 10-year median of 0.65 and 19.7% above the Drug Manufacturers industry median of 0.61. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current Equity-to-Asset is 0.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of $90.61 is trading 9.9% above its estimated GF Value™ of $82.42.
Key valuation signals for LABFF:
Equity-to-Asset: 0.73 (12% above median its 10-year median of 0.65)
GF Value™: $82.42 vs. price of $90.61 (9.9% above fair value)
Industry Position: 19.7% above the Drug Manufacturers median (#307 of 1007)
No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
93GF Score
Get the complete analysis for LABFF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABFF has been successfully added to your 
